Pivotal Results from Phase III Trial Show That the Combination of Ipilimumab and Nivolumab Increases Overall Survival in People with Kidney Cancer
Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo®) and ipilimumab (Yervoy®) significantly increased overall survival versus treatment with sunitinib (Sutent®) alone, according...
21-Mar-2018 11:00 AM EDT Add to Favorites
Updated Data Confirms a Durable 75 Percent Overall Response Rate, by Blinded Independent Review, of Larotrectinib in Adults and Children with Tumors Harboring TRK Fusions
Larotrectinib, a highly selective TRK kinase inhibitor, shows rapid, potent, and durable efficacy in both adult and pediatric patients with solid tumors that harbor TRK fusions, regardless of tumor type or patient age, according to results from...
22-Feb-2018 10:05 AM EST Add to Favorites
Increased Breast Cancer Risk Seen in Postmenopausal Women with High Body-Fat Levels Despite Normal BMI
The risk of invasive breast cancer is increased in postmenopausal women with a normal body mass index (BMI) but higher levels of body fat, meaning that a large portion of the population has an unrecognized risk of developing cancer.
9-Feb-2018 12:05 PM EST Add to Favorites
Viviane Tabar, MD, Named Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center
Viviane Tabar, MD, has been named the new Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center (MSK). Dr. Tabar has been a vital faculty member at MSK for more than 15 years and is currently the Theresa C. Feng Chair for...
5-Dec-2017 3:45 PM EST Add to Favorites
MSK-IMPACT™ Is the First Tumor-Profiling Multiplex Panel Authorized by the FDA, Setting a New Pathway to Market for Future Oncopanels
The US Food and Drug Administration (FDA) announced today the authorization of MSK-IMPACT™ (which stands for integrated mutation profiling of actionable cancer targets), a high throughput, targeted-DNA-sequencing panel for somatic mutations....
15-Nov-2017 1:00 PM EST Add to Favorites
Memorial Sloan Kettering (MSK) has named three investigators as recipients of this year’s Paul Marks Prize for Cancer Research. The award recognizes promising investigators aged 45 or younger at the time of nomination for their efforts in...
9-Nov-2017 9:05 AM EST Add to Favorites
New Study Findings Unlock the Secret of Why Some People with Pancreatic Cancer Live Longer than Others
The pancreatic cancer and immunotherapy experts at Memorial Sloan Kettering Cancer Center (MSK) have shown for the first time why some people with pancreatic cancer live many more years than others with the deadly disease.
7-Nov-2017 1:05 PM EST Add to Favorites
The US Food and Drug Administration (FDA) has announced that it has approved the drug vemurafenib for the treatment of patients with BRAF V600-mutant Erdheim-Chester disease (ECD). This is the first approval of a targeted therapy based on a basket...
6-Nov-2017 11:05 AM EST Add to Favorites
see all news
2-Dec-2014 12:35 PM EST
9-Dec-2013 9:05 AM EST
3-Dec-2013 3:15 PM EST
20-Sep-2013 2:00 PM EDT
12-Mar-2013 6:00 PM EDT
28-Sep-2012 12:40 PM EDTsee all experts